Brigatinib-4002
Recruiting
A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)
Clinicaltrials.gov
#NCT05721950About this clinical trial
The main aim of this study is to learn about the time between the start and stop of treatment with brigatinib in Chinese participants with non-small-cell lung cancer (NSCLC) and who have been positively diagnosed with having the anaplastic lymphoma kinase (ALK) gene. Other study aims are to learn about the progression of NSCLC and participants' response to treatment with brigatinib.
CN
Observational clinical trial.
At a glance
What medical conditions are being studied?
Non-small Cell Lung Cancer (NSCLC)
What is the clinical trial testing?
Brigatinib
How many participants are being enrolled?
200
Are placebos part of the clinical trial?
No
When is the clinical trial being conducted?
Jan 2024 - Dec 2026
How long is participation in the clinical trial?
Participants will be in this study until up to 36 months after first having been treated with brigatinib.
Key requirements
Sex
All
Age
18+ years
Healthy volunteers?
No
Entry criteria
Men and women (Age ≥ 18 years) can take part in this study.
Must have been diagnosed with non–small-cell lung cancer (NSCLC)
Must have changes in their genetic material (named anaplastic lymphoma kinase (ALK) gene) confirmed from medical records that are obtained from local hospital.
Must have been treated with brigatinib as the first treatment between September 2022 – December 2023
Cannot have received 1 treatment of an anticancer therapy
Cannot have been diagnosed with another cancer in addition to NSCLC within the last 5 year
Additional entry criteria will be discussed by the study doctor.
Locations
Location
Status
Recruiting